Read More

Neurocrine Biosciences Presents Data At MDS International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Comparable Improvement Over Time In Tardive Dyskinesia Severity And Impact Following Treatment With INGREZZA Capsules

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today presented findings from a data analysis of KINECT®-4 demonstrating a comparable pattern of improvement over time of clinician-rated tardive dyskinesia (TD)